Gene therapy study for CPVT heart condition
Part of Heart & circulation clinical trials.
This trial tests a new gene therapy called SGT-501 for people with a genetic heart condition called CPVT, which can cause dangerous fast heartbeats. The goal is to see if the treatment can reduce these episodes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with CPVT based on tests showing abnormal heart rhythms during exercise.
- You have a specific change in the RYR2 gene that is known to cause CPVT.
- You have had a serious heart rhythm event like cardiac arrest, fainting due to arrhythmia, or a sustained fast heartbeat.
- You take a stable dose of a beta-blocker and/or flecainide (heart medications) for at least one month before screening.
- You have had a recent exercise test showing a certain level of heart rhythm problems.
- You are up to date on meningococcal vaccine or willing to get it.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called AGP100 for people with CPVT, a genetic heart condition that causes dangerous heartbeats during exercise. The goal is to see if AGP100 can safely reduce these abnormal heart rhythms.
This study tests an experimental drug called CRD-4730 for people with CPVT, a rare inherited heart rhythm disorder that can cause dangerous fast heartbeats during exercise or stress. The trial will see if the drug can help control these abnormal heart rhythms better than current treatments.
This trial tests a new gene therapy called TN-401 for people with ARVC caused by a specific PKP2 gene mutation. The goal is to see if the treatment is safe and can help reduce dangerous heart rhythms.
This study looks at the risk of a fast heart rhythm (ventricular tachycardia) in people with genetic heart muscle diseases. It tests whether having a specific genetic change affects the success of a heart ablation procedure.
This trial tests a new gene therapy (XC001) delivered through a thin tube into your heart's blood vessels. It aims to grow new blood vessels to relieve chest pain in people with chronic angina who have no other treatment options.
This trial tests a one-time gene therapy for people with heart failure who still have normal pumping strength (preserved ejection fraction). It aims to improve how heart cells handle calcium, which may help the heart relax better and ease symptoms.
Hear when a new Catecholaminergic Polymorphic Ventricular Tachycardia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.